Momenta Pharma CEO: Q3 royalty rev from enoxaparin sodium injection disappoints

theflyonthewall.com

CEO Craig Wheeler commented: "Royalty revenues from enoxaparin sodium injection in Q3 were disappointing and reflected the market realities of a more competitive multi-player dynamic. We continue to invest in our promising development pipeline of complex generics, biosimilars and novel drugs."

View Comments (0)